X-ray of human kidneys. It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term. Compared with sunitinib, the combination of ...

At about 4 years of follow-up, first-line treatment with lenvatinib and pembrolizumab continued to confer a benefit over sunitinib monotherapy in patients with advanced renal cell carcinoma. Updated ...

A review of clinical trial data on combination treatments for clear cell renal cell carcinoma. Chung-Han Lee, MD: One of the common approaches in addition to doing dual immune checkpoint inhibitors is ...

This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with RCC whose disease progressed on or after ...

Eisai announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2026 ...

For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the ...

Patients with kidney cancer in Europe who are not responding to treatment will soon have two new options to try, as cabozantinib (Cabometyx, Ipsen Pharma) and lenvatinib (Kisplyx, Eisai Europe Ltd) ...

Clinical nurse Kiran Virdee explains why a multidisciplinary treatment approach to clear cell renal cell carcinoma is beneficial. Chung-Han Lee, M.D.: Ms. Virdee, can you speak a little about the role ...

The US Food and Drug Administration (FDA) has approved lenvatinib (Lenvima, Eisai), in combination with everolimus, for the treatment of patients with advanced renal cell carcinoma who were previously ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary Cancers Symposium later this week in San Francisco, California. The new ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral ...